STOCK TITAN

[Form 4] Genelux Corporation Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Joseph Cappello, Chief Technical Officer of Genelux Corporation (GNLX), reported insider awards and holdings following transactions dated 08/27/2025. He was granted 107,500 restricted stock units (RSUs) that convert to one share each upon vesting and received a stock option covering 142,500 shares with an exercise price of $3.64 and an expiration date of 08/26/2035. After these transactions he beneficially owns 159,766 shares of common stock and 142,500 option shares. The RSUs vest 25% after one year and then in 12 equal quarterly installments; the option vests 25% after one year and then in 36 equal monthly installments.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine executive equity awards align management incentives with shareholders without immediate dilution or cash proceeds.

The Form 4 shows standard equity compensation: RSUs and time-based stock options granted to the CTO on 08/27/2025. Vesting schedules (25% at one year then quarterly or monthly thereafter) are conventional and designed to retain the executive. The option exercise price of $3.64 sets a future incentive dependent on share-price appreciation. This filing is a common disclosure of insider compensation and does not indicate unusual governance concerns by itself.

TL;DR: Material only as insider ownership disclosure; no immediate cash flow impact and no exercised options reported.

The report records acquisition of 107,500 RSUs and grant of an option for 142,500 shares exercisable through 2035 at $3.64. Post-transaction beneficial ownership totals 159,766 common shares and 142,500 option shares. There is no sale or exercise reported, so no immediate dilution or proceeds. Investors should view this as management alignment rather than a liquidity event.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cappello Joseph

(Last) (First) (Middle)
C/O GENELUX CORPORATION
2625 TOWNSGATE ROAD, SUITE 230

(Street)
WESTLAKE VILLAGE CA 91361

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GENELUX Corp [ GNLX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Technical Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/27/2025 A(1) 107,500 A $0 159,766 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $3.64 08/27/2025 A 142,500 (2) 08/26/2035 Common stock 142,500 $0 142,500 D
Explanation of Responses:
1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter.
2. The shares subject to the option will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 36 equal monthly installments thereafter.
/s/ Joseph Cappello 08/29/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Genelux Corp

NASDAQ:GNLX

GNLX Rankings

GNLX Latest News

GNLX Latest SEC Filings

GNLX Stock Data

117.16M
39.85M
Biotechnology
Pharmaceutical Preparations
Link
United States
WESTLAKE VILLAGE